Wang Yongkang, Yang Yinfeng, Gao Honglei, Ouyang Ting, Zhang Luyao, Hu Jili, Hu Sheng, Kan Hongxing
School of Medical Informatics Engineering, Anhui University of Chinese Medicine, Hefei, China.
Anhui Computer Application Research Institute of Chinese Medicine, China Academy of Chinese Medical Sciences, Hefei, China.
Front Oncol. 2021 Feb 16;10:566183. doi: 10.3389/fonc.2020.566183. eCollection 2020.
As essential components of cycle growth, the cell division cycle-associated family genes (CDCAs) have crucial roles in tumor development and progression, especially in hepatocellular carcinoma (HCC). However, due to the tumor heterogeneity of HCC, little is known about the methylation variability of CDCAs in mediating phenotypic changes (e.g., immune infiltrates) in HCC. Presently, we aim to comprehensively explore the expression and prognosis of CDCAs methylation with regard to immune infiltrates of HCC.
We first identified the correlating differentially expressed genes (co-DEGs) among 19 different types of cancer cohorts (a total of 7,783 patients) and then constructed the weighted gene co-expressed and co-methylated networks. Applying the clustering analysis, significant modules of DEGs including CDCAs were selected and their functional bioinformatics analyses were performed. Besides, using DiseaseMeth and TIMER, the correlation between the methylation levels of CDCAs and tumor immune infiltrates was also analyzed. In final, to assess the influence of CDCAs methylation on clinical prognosis, Kaplan-Meier and Cox regression analysis were carried out.
A total of 473 co-DEGs are successfully identified, while seven genes of CDCAs (CDCA1-3 and CDCA5-8) have significant over-expression in HCC. Co-expressed and co-methylated networks reveal the strong positive correlations in mRNA expression and methylation levels of CDCAs. Besides, the biological enrichment analysis of CDCAs demonstrates that they are significantly related to the immune function regulation of infiltrating immune cells in HCC. Also, the methylation analysis of CDCAs depicts the strong association with the tumor immunogenicity, i.e., low-methylation of CDCA1, CDCA2, and CDCA8 dramatically reduced the immune infiltrate levels of T cells and cytotoxic lymphocytes. Additionally, CDCA1-6 and CDCA8 with low-methylation levels significantly deteriorate the overall survival of patients in HCC.
The co-expressed and co-methylated gene networks of CDCAs show a powerful association with immune function regulation. And the methylation levels of CDCAs suggesting the prognostic value and infiltrating immune differences could be a novel and predictive biomarker for the response of immunotherapy.
作为细胞周期生长的重要组成部分,细胞分裂周期相关家族基因(CDCAs)在肿瘤发生发展中起着关键作用,尤其是在肝细胞癌(HCC)中。然而,由于HCC的肿瘤异质性,关于CDCAs甲基化在介导HCC表型变化(如免疫浸润)中的变异性知之甚少。目前,我们旨在全面探讨CDCAs甲基化与HCC免疫浸润相关的表达及预后情况。
我们首先在19种不同类型的癌症队列(共7783例患者)中鉴定出相关的差异表达基因(共差异表达基因),然后构建加权基因共表达和共甲基化网络。应用聚类分析,选择包括CDCAs在内的共差异表达基因的显著模块并进行功能生物信息学分析。此外,使用DiseaseMeth和TIMER分析CDCAs甲基化水平与肿瘤免疫浸润之间的相关性。最后,为评估CDCAs甲基化对临床预后的影响,进行了Kaplan-Meier分析和Cox回归分析。
成功鉴定出473个共差异表达基因,而CDCAs的7个基因(CDCA1 - 3和CDCA5 - 8)在HCC中显著过表达。共表达和共甲基化网络揭示了CDCAs mRNA表达与甲基化水平之间的强正相关。此外,CDCAs的生物富集分析表明它们与HCC中浸润免疫细胞的免疫功能调节显著相关。而且,CDCAs的甲基化分析显示与肿瘤免疫原性密切相关,即CDCA1、CDCA2和CDCA8的低甲基化显著降低了T细胞和细胞毒性淋巴细胞的免疫浸润水平。此外,低甲基化水平的CDCA1 - 6和CDCA8显著恶化了HCC患者的总生存期。
CDCAs的共表达和共甲基化基因网络与免疫功能调节密切相关。CDCAs的甲基化水平提示了预后价值和免疫浸润差异,可能是免疫治疗反应的一种新型预测生物标志物。